DSC Advisors’s Foamix Pharmaceuticals Ltd. Ordinary Shares FOMX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-3,365,000
| Closed | -$11.2M | – | 88 |
|
|
2019
Q4 | $11.2M | Buy |
3,365,000
+302,407
| +10% | +$961K | 5.37% | 8 |
|
|
2019
Q3 | $9.31M | Buy |
3,062,593
+732,193
| +31% | +$2.06M | 1.84% | 11 |
|
|
2019
Q2 | $5.55M | Buy |
2,330,400
+392,676
| +20% | +$1.17M | 0.97% | 20 |
|
|
2019
Q1 | $7.27M | Buy |
+1,937,724
| New | +$7.26M | 1.34% | 13 |
|
|
2018
Q4 | – | Sell |
-1,721,378
| Closed | -$9.9M | – | 88 |
|
|
2018
Q3 | $9.9M | Buy |
1,721,378
+533,774
| +45% | +$3.05M | 1.32% | 14 |
|
|
2018
Q2 | $5.95M | Hold |
1,187,604
| – | – | 0.97% | 18 |
|
|
2018
Q1 | $6.09M | Hold |
1,187,604
| – | – | 1.28% | 15 |
|
|
2017
Q4 | $7.14M | Hold |
1,187,604
| – | – | 4.14% | 7 |
|
|
2017
Q3 | $6.59M | Buy |
1,187,604
+950
| +0.1% | +$4.91K | 2.1% | 12 |
|
|
2017
Q2 | $5.51M | Hold |
1,186,654
| – | – | 1.81% | 15 |
|
|
2017
Q1 | $5.87M | Sell |
1,186,654
-373,346
| -24% | -$3.59M | 4% | 13 |
|
|
2016
Q4 | $17.3M | Sell |
1,560,000
-107,377
| -6% | -$1.01M | 9.82% | 1 |
|
|
2016
Q3 | $15.4M | Buy |
1,667,377
+169,166
| +11% | +$1.41M | 9.38% | 1 |
|
|
2016
Q2 | $9.5M | Buy |
1,498,211
+3,812
| +0.3% | +$25.3K | 5.99% | 4 |
|
|
2016
Q1 | $9.7M | Buy |
1,494,399
+85,802
| +6% | +$553K | 5.79% | 4 |
|
|
2015
Q4 | $11.4M | Buy |
1,408,597
+408,597
| +41% | +$3.05M | 5.97% | 5 |
|
|
2015
Q3 | $7.33M | Buy |
1,000,000
+15,266
| +2% | +$156K | 3.56% | 6 |
|
|
2015
Q2 | $10.1M | Buy |
984,734
+113,081
| +13% | +$1.25M | 5.25% | 5 |
|
|
2015
Q1 | $8.06M | Buy |
871,653
+603,343
| +225% | +$5.4M | 4.28% | 5 |
|
|
2014
Q4 | $1.88M | Buy |
268,310
+52,414
| +24% | +$300K | 1.09% | 24 |
|
|
2014
Q3 | $1.18M | Buy |
+215,896
| New | +$1.24M | 0.59% | 36 |
|
DSC Advisors's FOMX Position: Q1 2020 in Review
DSC Advisors sold out of Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) in Q1 2020, closing a stake of 3,365,000 shares — an estimated $11.2M sold.
DSC Advisors first reported a position in FOMX in Q3 2014 and held it in 21 quarters. The position peaked at $17.3M in Q4 2016. 3 funds tracked by Wall St. Rank hold FOMX as of Q1 2020.
- DSC Advisors reported no remaining Foamix Pharmaceuticals Ltd. Ordinary Shares position as of Q1 2020 after selling out during the quarter.
- DSC Advisors sold 3,365,000 Foamix Pharmaceuticals Ltd. Ordinary Shares shares in Q1 2020, an estimated $11.2M.
- DSC Advisors first reported a position in Foamix Pharmaceuticals Ltd. Ordinary Shares in Q3 2014 and held it in 21 quarters.
- DSC Advisors's Foamix Pharmaceuticals Ltd. Ordinary Shares position peaked at $17.3M in Q4 2016.
- 3 funds tracked by Wall St. Rank held Foamix Pharmaceuticals Ltd. Ordinary Shares as of Q1 2020.
Based on DSC Advisors's 13F filing for Q1 2020, filed 15 May 2020.